Cormedix Inc.

Ethicon, Gmbh

Robert DiLuccio

Modesto Erneta

Bruce Reidenberg

Dennis D Jamiolkowski

Z Paul Lorenc

Randy Milby

Antony Pfaffle

Paul Z Lorenc

A method for the prevention or elimination of biofilm microorganisms on at least one surface of a medical device, the method comprising the steps of: (a) providing a biofilm-active composition having at least one biofilm-active agent; and (b) delivering the biofilm-active composition to the medical device in an amount sufficient to prevent or eliminate the biofilm microorganisms on at least one surface of the medical device.

Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms

A method for treating a cancer which overexpresses any of N-myc genes, C-myc genes and/or L-myc genes in a mammalian body, the method comprising: administering a composition to the mammalian body, wherein the composition comprises at least one from the group consisting of taurolidine; taurultam; taurinamide; methylene glycol; taurultam and taurinamide in a ratio of 1 taurultam:7 taurinamide; and taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam:7 taurinamide:1 methylene glycol.

Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies

A method for treatingin blood, comprising administering to the blood taurolidine, and/or one or more taurolidine derivatives, in a concentration which is effective to treatin the blood.

Methods and pharmaceutical compositions for treating candida auris in blood

Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.

Neuroblastoma treatment with taurolidine hydrolysis products

An antimicrobial suture comprising a filament and taurolidine.

Antimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same

Placement of a vascular access device (intravenous, intra-arterial and/or intra-osseous vascular access) in a non-sterile environment greatly increases the risk of infection via the vascular access device. This invention provides an approach for accomplishing sterilization of the site where vascular access will be attempted under non-sterile field conditions. In addition, this invention provides a sterile vascular connector pre-loaded with an antimicrobial, e.g., Taurolidine. Use of the vascular connector provides the antimicrobial concurrently with achieving vascular access, which limits the risk of infection despite access placement under non-sterile field conditions.

Field sterilizer and vascular connector kit

Absorbable microspheres comprising a copolymer formed from greater than 80 to about 99 mole percent D,L-lactideg, L(&#x2212;)-lactide, D(+)-lactide, or meso-lactide and combinations thereof, and about 1 to less than 20 mole percent of a different second monomer selected from the group consisting of p-dioxanone and trimethylene carbonate and combinations thereof, said microspheres having a particle size ranging from about 5 to 2000 microns. Also described herein are formulations comprising such absorbable microspheres.

High-glass transition temperature absorbable microspheres

An antimicrobial composition comprising an ionic complex of an anionic polyester with an antimicrobial metal, wherein the anionic polyester has an ion exchange capacity from about 0.19 meq/g to about 1.0 meq/g.

Antimicrobial polymer compositions and the use thereof

Absorbable microspheres comprising a copolymer formed from greater than 80 to about 99 mole percent D,L-lactide, L(&#x2212;)-lactide, D(+)-lactide, or meso-lactide and combinations thereof, and about 1 to less than 20 mole percent of a different second monomer selected from the group consisting of p-dioxanone and trimethylene carbonate and combinations thereof, said microspheres having a particle size ranging from about 5 to 2000 microns. Also described herein are formulations comprising such absorbable microspheres.

Growing community of inventors

Haymarket, VA, United States of America

Robert DiLuccio